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ABSTRACT
Adenovirus vector is the most common used vector in clinical gene therapy.  The development 
of adenovirus from the first generation until the helper-dependent adenovirus vector has greatly 
reduced toxicity and immunogenicity.  The helper-dependent adenovirus can also prolong transgene 
expression.  Tissue- or disease-specific approach has been used to improve the specificity of adenoviral 
vector for cancer gene therapy.  This review summarizes some adenoviral gene therapy and targeting 
approaches available for human cancer as well as animal cancer.
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ABBREVIATIONS
Adenovirus (Ad) Human papillomavirus (HPV)
Alternative reading frame (ARF) Interferon (IFN) 
Arg-Gly-Asp (RGD) Interleukin 2 (IL-2)
Carcinoembryonic antigen (CEA) Interleukin 12 (IL-12)
Complementary DNA (cDNA) Non-small-cell lung cancer (NSCLC)
Coxsackie adenovirus receptor (CAR) Tumour necrosis factor (TNF)
Cytomegalovirus (CMV) Tumour protein 53 (p53)
INTRODUCTION
Adenoviruses (Ad) are among the most commonly used vectors for the delivery of genetic material 
into human and animal cells, and in selected stable germ-line (Stephan and Kelly, 2002; Takehashi 
et al., 2006).  In addition, adenoviruses have a number of advantages as vectors; these include a 
rapid infection of both dividing and non-dividing cells, DNA stability, ease of manipulation and 
propagation, and low pathogenicity in humans.  Adenoviruses became the most widely used vector 
for gene therapy clinical trials in 2009, with 23.9% out of a total 1579 clinical trials (Michael, 
2009), especially for cancer gene therapy using intratumoral injection (Shirakawa, 2008).
Over the years, Ad vectors have been passed through a serial of evolution mounting evidence 
of anti-Ad immunological responses (both innate and adaptive) prompted the development of 
improved Ad versions (Hartman et al., 2007).  The first generation adenovirus vectors were 
developed by deleting one or two early genes, E1 and/or E3.  This vector induced strong host 
immune responses that rapidly remove transgene expression, and thus gene expression became 
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low and could only offer transient gene expression (Cao et al., 2004).  Newer Ad vectors have 
improved the ability to persist in vivo, facilitating the avoidance of adaptive immune responses 
(Hartman et al., 2007).  An additional deletion in the early genes, E2 and/or E4 was manipulated 
for the second and third generation vectors (Zhou et al., 1996).  Meanwhile, toxicity was found to 
be reduced in animal models with these vectors (Lusky et al., 1998; O’Neal et al., 1998; Andrews 
et al., 2001).  The deleted all viral genes’ helper-dependent adenoviruses, which contain solely the 
cis acting elements, were the most advanced vector that has been developed (Morsy and Caskey, 
1999).  These Ad vectors improve the prospects for a long-term gene therapy (Morsy and Caskey, 
1999).
In March 2003, 63.4% of all the gene therapy clinical trials were for cancer according to 
the Journal of Gene Medicine (Clare et al., 2003).  Two adenoviral-based gene therapeutics for 
cancer treatment have been commercialized in China (Peng, 2005; Yu and Fang, 2007).  These two 
constructs have been used as alternative treatments for cancer, in combination with chemotherapy 
in China (Shirakawa, 2008).  This article summarizes the use of adenovirus in the preclinical and 
clinical trials of cancer gene therapy.
ADENOVIRUS BASED GENE THERAPY IN HUMAN CANCER
Colon Cancer
Colon cancer is the third most frequent cancer for both men and women in Malaysia, which accounts 
for 7.8% and 5.6% respectively for the two genders (NCR, 2002).  The main treatment for colon 
cancer is surgical resection of the entire tumour, but the result often remains unsatisfactory due to 
the metastases of the tumour (Faye et al., 2000).  Thus, gene therapy may provide an alternative 
approach to the conventional treatment.
In particular, p53 protein acts as a multifunctional regulator for the cell cycle that is capable 
of causing apoptosis and becoming tumour suppressor (Levine, 1997).  Harris et al. (1996) have 
used adenovirus encoding wild type TP53, a gene that encoded p53 protein, as their construct for 
their colon cancer study.  The researchers found a complete regression and a doubling survival 
time as compared to the control mice model with intratumoral injection of the construct to the 
subcutaneous implant p53-mutated colon cancer mice model.  A phase I clinical trial, with this 
construct, showed no tumour regression but with the combination with chemotherapy, those 
patients revealed partial responses to the treatment (Veenok et al., 1998).
Meanwhile, anti-tumour effects were shown in the murine model with liver metastases colon 
cancer cell line transduced with adenovirus encoding IL-12 (Caruso et al., 1996).  There was a 
synergistic effect found in a combination treatment of adenovirus encoding TP53 and chemotherapy 
in immunodeficiency mice (Ogawa et al., 1997).
Carcino-embryonic antigen (CEA) is a cell surface protein that was presumed to play a role 
in cellular adhesion.  Richards et al. (1995) found the over-expressing of CEA in 90% of the 
colon cancer cells, but this was only at a low level in the normal cells.  Lan et al. (1996: 1997) 
have developed adenovirus with CEA promoter to provide tumour specific transgene expression. 
However, the researchers found that the gene expression of this modified vector was weaker 
compared with the non-specific cytomegalovirus (CMV) promoter.  With that, the development of 
tumour specific vector that is capable of maintaining the transgene expression remains challenging.
Lung Cancer
Lung cancer is the most common cancer among Malaysian men, with 13.9% of all the male cancer 
patients in the year of 2002 (NCR, 2002).  Besides, lung cancer is also in the list of the most 
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frequent cancers in women, which was ranked at number six, with 4.3% of all the women cancer 
patients in 2002 (NCR, 2002).  Thus, it is important to find an alternative treatment for lung cancer 
other than the conventional treatment that is available at present.  The progressively delineated of 
the molecular biology of lung cancer, over the past three decades, has allowed the development of 
lung cancer gene therapy towards targeting (Toloza, 2005).  Adenoviruses, with a tropism for lung 
cancer cells (Stratford-Perricaudet and Perricaudet, 1994), have gained an advantage as a gene 
therapy vector for lung cancer.
Swisher et al. (1999) designed a Phase I clinical trial using adenovirus encoding wild-type 
TP53 cDNA for advanced non-small-cell lung cancer (NSCLC) after finding a tumour regression 
in the animal model, following the intratumoral injection of the construct.  From this study, the 
authors concluded that repeated intratumoral injection of the E1-deleted replication-defective 
recombinant adenovirus containing wild-type TP53 was well tolerated, while transient transgene 
expression was found to mediate the patients’ anti-tumour activity.  Besides, vector-related adverse 
events were also found to be minimal.
The targeting approach for lung cancer, with the use of adenovirus vector such as adenovirus 
vector with double expression cassette consisting of secretory leukoprotease inhibitor promoter 
gene that is highly expressed in almost all NSCLCs and CMV promoter (Maemondo et al., 
2004), adenovirus-mediated herpes simplex virus thymidine kinase (Fukunaga et al., 2002) and 
polylysine coated adenovirus encoding proto-oncogenec-kit (Schwarzenberger et al., 1996) have 
shown a promising result for lung cancer treatment.
Breast Cancer
Breast cancer is the most frequent cancers among the women in Malaysia (NCR, 2002).  According 
to the NCR database, 30.4% of the females in Malaysia were newly diagnosed breast cancer 
patients in the year 2002.  A Malaysian woman has 1 in 19 chances of getting breast cancer in 
her life time (NCR, 2002).  Therefore, it is crucial to develop a gene therapy treatment for breast 
cancer due to the limited success of conventional treatment (Zhang et al., 1996).
Zhang et al. (1996) developed an adenovirus containing human interferon consensus gene and 
tested it on human breast cancer (MDA-MB-435) implanted nude mice.  A complete regression, 
accompanied by the decreased of p53 gene expression, was found in this study.  They also found 
a partial regression of the tumour in the control group, based on which, they concluded that the 
rapid regression of the breast tumour was due to the combination of the virus oncolysis and the 
effectiveness of the interferon gene therapy.
An alternative product from the family of cyclin-dependent kinase inhibitors, human INK4a/
ARF (alternative reading frame) locus, p14ARF, has been identified as a potent tumour suppressor for 
both in vitro and in vivo (Serrano et al., 1996; Kamijo et al., 1997; Sherr, 2000).  Overexpression of 
p14ARF will result in cell cycle arrest (Quelle et al., 1995; Kamijo et al., 1997; Weber et al., 2002) 
and apoptosis (Radfar et al., 1998; Yang et al., 2000; Hemmati et al., 2002).  Deng et al. (2002) 
constructed a recombinant adenovirus expressed human p14ARF cDNA for the treatment of human 
breast cancer.  They found an increase in the number of cells in the G0/G1 phase but a decrease in 
the S and G2/M phases during the time-course study.  In addition, there was an increased amount 
of p53 at the same time.  Besides, the findings of their study also indicated a significant increase in 
the sensitivity of the cells to chemotherapy drug upon p14ARF recombinant adenovirus expression.
A study that evaluated the infection efficiencies of three most promising vectors, namely 
human adenovirus type 5, canine adenovirus type 2, and human adeno-associated type 2 vectors, 
was carried out by Lucas et al. (2003) in breast cancer cell lines.  Meanwhile, the real-time PCR, 
flow cytometry and antibody blocking studies achieved an agreement in this study that coxsackie 
adenovirus receptor (CAR) or αv integrin levels are not the main influence to the infection 
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efficiencies of human adenovirus vector and canine adenoviral vector.  They concluded that human 
adenovirus vector served as the best choice of carrier for gene therapy as compared to canine 
adenovirus vector and human adeno-associated vector due to the excellent infection efficacy of the 
human adenovirus vector.  This was supported by a study by Mountain (2000), in which a majority 
of more than 3500 patients who had been enrolled in cancer gene therapy trials approaches were 
found to have used human adenovirus.
Prostate Cancer
Prostate cancer ranks as the sixth most frequent cancers among men in Malaysia and this accounted 
for 5.7% in 2002 (NCR, 2002).  As for males above the age of 70 years, prostate cancer becomes 
the top two most common cancers (NCR, 2002).  In United States, prostate cancer is the second 
leading cause of cancer deaths in men (ACS, 2005).  The slow growth rate of the prostate cancer as 
compared with other solid tumour (Schmid et al., 1993) caused no major improvement in patient’s 
survival with chemotherapy (Visakorpi et al., 1991; Kallioniemi et al., 1991).  Gene therapy might 
be an alternative treatment choice for prostate cancer or in combination with conventional therapy 
to prolong the survival rate of prostate cancer patients.
Tissue- or disease-specific treatments have gained advantages for prostate cancer in gene 
therapy. The were an estimated 200 prostate-specific genes available for transcriptionally targeting 
prostate cells (Xu et al., 2001; Nelson et al., 2000).  Meanwhile, cancer-specific gene mutation 
such as p53 (Navone et al., 1993; Bookstein et al., 1993; Brooks et al., 1996) added advantage 
to prostate-targeting therapy.  Adenovirus vector provides a highly tailored therapy that gives 
different qualities to prostate cancer cell (Lupold and Rodriguez, 2005).  Promising results have 
been reported in several studies, involving the use of oncolytic and suicide gene therapy strategies 
(Lupold and Rodriguez, 2005).  In particular, oncolytic virotherapy uses adenovirus that selectively 
kills cancer cells by competent replication in tumour cells, but not in normal cells (Hemminki et 
al., 2003).  Thus, a strong cytolytic effect is achieved by oncolytic virotherapy that targets cancer 
cells (Meerani and Yang, 2010).  On the other hand, adenovirus can be used as a vector in suicide 
gene therapy to deliver non-toxic gene or prodrug to the cancer cells, which eventually triggers the 
maximum therapeutic effect with limited systemic toxicity (Yazawa et al., 2002).  A combination 
of radiation therapy with replicating adenoviruses shows synergistic effects to radiation and this 
study is in phases I and II of clinical trials (Freytag et al., 2007).
Ovarian Cancer
Ovarian cancer is the fourth most common cancers among women in Malaysia, and this constituted 
about 5.0% of the total female cancer (NCR, 2002).  Ovarian cancer is also the fourth leading 
cause of gynaecology malignancy deaths among the female population (Greenlee et al., 2001). 
The lack of effective screening strategies and the unavailability of clear symptoms at the early 
stage of the disease caused 70% of the women to be at the advanced stage at the time of get initial 
diagnosis (Barnes et al., 2002).  This leads to the low long-term survival rate over the past 20 years 
even when advanced surgical technique and chemotherapy are available (Barnes et al., 2002). 
With that, more advanced gene therapy might be a choice to increase the survival rate of ovarian 
cancer patients.    
The deficiency of coxsackie adenovirus receptor (CAR) in ovarian cancer cells has caused 
a relative resistance of ovarian cancer cells to adenovirus infection (Vanderkwaak et al., 1999). 
Retargeting adenovirus receptor to a common receptor of ovarian cancer cells is crucial to improve 
the tropism of the adenovirus vector to ovarian cancer cells.  Wickham et al. (1993) added RGD 
peptide sequences into the penton base with the secondary host cell receptor integrins.  Meanwhile, 
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Vanderkwaak et al. (1999) found the RGD-modified adenoviral vector to have shown a promising 
gene expression to primary ovarian cancer cells compared to human mesothelial tissue.
Cervical Cancer
Cervical cancer was ranked among the most common cancers in Malaysian female population in 
2002.  The cancer of cervix uteri is the second most common among Malaysia women, comprising 
of 12.0% of the total female cancers (NCR, 2002).  Malaysia had higher age-standardized incidents 
of cervical cancer as compared to western countries and other countries in Asia (NCR, 2002). 
Nonetheless, the reason for the high age-standardized incidents in Malaysia remains unknown and 
it requires further investigation.
Human papillomavirus (HPV) has generally been recognized as the main contributor to 
cervical cancer.  Hamada et al. (1996) found that the recombinant adenoviral incorporated wild 
type p53 was a potential therapy for HPV-positive cervical cancer cells.  Further evaluation by 
Woong et al. (2002) indicated significant cell growth suppression by p53 recombinant adenovirus 
in HPV 18-infected cells (HeLa and HeLaS3) as compared to HPV 16-infected cells (CaSki and 
SiHa).  Besides, the researchers also concluded that different cancer cell lines would have different 
cell cycles arrest phases and different roles of cell growth suppression through apoptosis in the 
event of over-expression of wild type p53 in those cell lines.
Table 1 summarizes the clinical trials in cancer gene therapy involving adenoviral vector. 
Adenovirus is the most used vector for cancer gene therapy in those trials.
ADENOVIRAL-BASED GENE THERAPY FOR ANIMAL CANCER
Canine 
Biological and environmental similarities among dogs and humans have made dogs one of the 
appropriate preclinical models for gene therapy (Kruth, 1996).  Andrawiss et al. (1999) studied the 
potential of adenoviral gene transfer in dog prostate, aiming that dog as a basic preclinical model 
for human prostate cancer gene therapy.  The researchers found transgene expression in prostates 
and epithelial cells with no side effects on the dogs.
Meanwhile, Von Euler et al. (2008) have reported the usage of adenoviral vector for the gene 
therapy in canine malignant melanoma.  Two dogs with oral and conjunctiva malignant melanoma 
respectively were given recombinant adenovirus encoding human CD40L gene as a treatment. 
CD40L protein is a member of the tumour necrosis factor (TNF) that is mainly expressed on 
activated T cells.  The dog with oral melanoma was in stage III at the time it was diagnosed.  This 
dog showed a complete regression of melanoma after 2 intratumoral injections of recombinant 
adenovirus.  However, no recurrence of the tumour and no abnormality were found after the gene 
therapy.  The other dog with conjunctival melanoma was in stage I with a rapid progression.  This 
dog was treated with the same recombinant adenovirus just like the dog with oral melanoma but 
it was given 6 injections over 60 days.  The tumour regressed dramatically within 60 days of post 
treatment with no sign of progression or metastasis.  Adenoviral immunotherapy was efficient 
for canine melanoma and could be considered for human melanoma treatment, especially when 
aggressive surgical excision shortens the survival life span (< 10 months) (Dow et al., 1998; 
MacEwen et al., 1999).
Canine osteosarcoma is the most common cancer in large dogs, with over 8000 cases in 
Unites States annually and there is no curative treatment for this particular disease at the moment 
(Hemminki et al., 2003).  Due to the unlikely replication of human adenovirus in canine cells, 
Hemminki et al. (2003) have generated the first non-human oncolytic adenovirus.  They found that 
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this virus could effectively kill the primary canine osteosarcoma cells from a dog that underwent 
osteosarcoma surgery.  Besides, the advantage of the in vivo therapeutic was attained from the 
development of this conditionally replicated canine adenovirus (Hemminki et al., 2003).
A preparation study for phase I clinical trail of the recombinant adenoviral gene therapy for 
locally recurrent prostate cancer was carried out by Dwyer et al. (2005).  This study showed no 
vector-related toxicity and the successful introduction of gene expression in the prostate gland of 
dogs.  More importantly, no animal experienced surgical complications and no significant change 
was shown in the serum chemistry panels following the therapy.  These results provide insight for 
further translation of this experiment into clinical setting.
 Lung, colon or breast cancer in canine is not a good model for human cancer.  This is due to 
the low prevalence of these cancers in dogs and the biologically difference of these organs between 
dog and human (Kruth, 1996).
Feline
Siddiqui et al. (2007) conducted a study using adenovirus harbouring feline interleukin-12 (IL-12) 
for feline soft tissue sarcomas gene therapy.  The study was in phase I clinical trial.  Thirteen cats 
with confirmed diagnosis of sarcoma underwent a gene therapy using recombinant adenovirus 
following a prior radiation therapy of 22 days.  The recombinant adenovirus cloned feline IL-12 
was intratumorally injected and the tumour was heated at 24-hours post-injection.  This clinical 
trial was carried out to check the systemic toxicity and tumour expression of IL-12.  From this 
study, Siddiqui et al. (2007) found that hyperthermia-induced gene therapy capable of localizing 
gene expression and limiting systemic toxicity.
 The successes in using adenovirus system for preclinical or clinical study in canine and feline 
species have provided future insight into the development of cancer vaccine for animals.  However, 
the unlikely replication of the human adenoviral vector in canine and feline cells might reduce the 
efficiency of vector.  Therefore, a study on Ad dosage is crucial to inhibit tumour progression or 
enhance tumour regression effectively.  Besides, the limited number of canine or feline in those 
trials might influence the validity of data.  More trials are required for validating the use of the Ad 
vector as a carrier for cancer gene therapy in canine or feline.
Hamster
Recombinant hamster interferon (IFN)-α adenovirus can effectively suppress hamster pancreatic 
tumour growth in Syrian hamster (Hara et al., 2007).  Tumour regression was discovered in both 
the injected subcutaneous tumours and untreated tumours in the peritoneal cavity and at distant 
sites.  No significant difference was found in the systemic toxicity among the treated and untreated 
groups.  Thus, local IFN- α gene therapy has been proven to be a promising therapeutic strategy 
for pancreatic cancer (Hara et al., 2007).
 Another study that made use of the Syrian golden hamster as a biliary cancer model was 
conducted by Kim et al. (2006) who used genetically modified bone marrow stromal cells 
containing adenoviral harbouring human interleukin-2 (IL-2) gene as a treatment.  All the hamsters 
in the treatment group survived with no evidence of disease during the 12 weeks’ observation 
period.  However, the hamsters in the untreated and control group showed disseminated metastases 
that involved lungs as early as 4 weeks.  Thus, the researchers made a conclusion that adenovirus 
vector carrying IL-2 as an effective treatment for biliary cancer.
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CONCLUSIONS
The advancing field of gene therapy promises survival remedies for the ever raising number of 
cancer patients worldwide.  Moreover, innovative and combinatory treatment of Ad gene therapies 
with the aid of the advanced molecular biology tools have shown promising results in the treatment 
of cancer.  Meanwhile, a continual evaluation on the specificity, transgene expression and safety of 
Ad gene therapy in cancer will ensure feasible approach for successful outcomes.
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